<DOC>
	<DOCNO>NCT00219232</DOCNO>
	<brief_summary>The goal research study evaluate , open-label extension phase , safety efficacy rivastigmine transdermal patch patient probable Alzheimer 's Disease</brief_summary>
	<brief_title>An Open-label Extension Evaluate Efficacy Safety Rivastigmine Transdermal Patch Patients With Probable Alzheimer 's Disease</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Rivastigmine</mesh_term>
	<criteria>Patients fulfil inclusion exclusion criterion list study CENA713D2320 complete doubleblind treatment phase study medication without significant protocol violation .</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Alzheimer 's disease</keyword>
	<keyword>Dementia</keyword>
</DOC>